Smallpox: The threat of bioterrorism and the risk of the vaccine

Neurology

Volumn 60, Issue 8, 2003, Pages 1228-1229

  Johnson, Richard T ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE;

BIOLOGICAL WARFARE; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; EDITORIAL; HAZARD ASSESSMENT; HUMAN; INFECTION RISK; LABORATORY; PRIORITY JOURNAL; RISK ASSESSMENT; SMALLPOX; SOMALIA; STORAGE; VACCINATION REACTION; VACCINIA VIRUS; VIROGENESIS;

EID: 0037461333     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.8.1228     Document Type: Editorial

References (6)

1. Institute of Medicine. Review of the Centers for Disease Control and Prevention's Smallpox Vaccination Program Implementation - Letter Report #1. National Academy of Sciences, 2003.
2. Centers for Disease Control. Vaccinia (Smallpox) vaccine. Recommendations of the Advisory Committee on Immunization Practices, 2001. Morb Mort Wkly Rpt 2001;50:1-25.
3. Tucker JB. Scourge: The Once and Future Threat of Smallpox. New York: Atlantic Monthly Press, 2001.
4. Nanning W. Prophylactic effect of antivaccinia gamma-globulin against post-vaccinal encephalitis. Bull Wld Hlth Org 1962;27:317-324.
5. Lane JM, Ruben FL, Neff JM, Millar JD. Complication of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970;122:303-309.
6. Booss J, Davis LE. Smallpox and smallpox vaccination: neurological implications. Neurology 2003;60:1241-1245.